2025.1.22

Optieum Biotechnologies, Inc. Strengthens Executive Leadership Team with Chief Scientific Officer and Chief Technology Officer Appointments

Ehime, Japan, January 22, 2025 – Optieum Biotechnologies Inc. (“Optieum”), a biotechnology company focused on discovering and developing innovative CAR-T cell therapies, today announced the appointment of Dr. Dan MacLeod to the role of Chief Scientific Officer (CSO) and Dr. Stewart Craig to the role of Chief Technology Officer (CTO), further strengthening our executive leadership team.

“We are thrilled to welcome Dan and Stewart to Optieum’s executive leadership team. Their combined deep expertise in cell and gene therapy product research, development and delivery will be instrumental in advancing our products into clinical trials,” said Shun Nishioka, Optieum’s President and Chief Executive Officer.

Dr. MacLeod is an experienced biotechnology leader and innovator in the cell therapy space with 20 years of experience in immunology, oncology, cancer immunotherapy, gene-editing and virology. Throughout his career, Dan has successfully led numerous teams in translating platform technologies into clinical candidate cell therapies, including four CAR-T therapies that advanced from early-stage research through IND-enabling studies and into Phase 1/2 clinical trials. Prior to joining the Optieum team, Dan was Senior Vice President of Discovery at ImmunoScape, where he led R&D for autologous TCR-T cell therapies. He also held roles of increasing responsibility during his time at Precision BioSciences, leading the discovery and development of gene-edited, allogeneic CAR-T cell therapies. Earlier in his career, Dan held roles at GlaxoSmithKline and the International AIDS Vaccine Initiative (IAVI).

Dr. Craig is an accomplished biotechnology professional with extensive experience in development, technical operations, quality systems and regulatory affairs for complex biologicals including over 30 years of experience in cell and gene therapy product manufacturing. He has held executive level positions designing, implementing and operating the CMC and GMP manufacturing infrastructure for various pioneering cell and gene therapy companies, including Orchard Therapeutics, Sangamo Therapeutics, Erytech Pharma and Xcyte Therapies. During his career, he has successfully led the development, manufacturing and clinical delivery of recombinant proteins, monoclonal antibodies, gene therapies and cell therapies, including activated T cells and gene-modified T cells.

“With its groundbreaking Eumbody System, Optieum is set to unlock the full therapeutic potential of CAR-T therapies. I’m thrilled to join this mission to bring transformative treatments to patients facing the most challenging diseases,” said Dr. MacLeod, CSO of Optieum Biotechnologies.

“I am honored to join Optieum and be a part of transitioning this innovative CAR-T platform into clinical trials,” said Dr. Craig, CTO of Optieum Biotechnologies.

About Optieum Biotechnologies Inc.

Optieum Biotechnologies Inc. is a cutting-edge biotechnology company dedicated to engineering hope for patients through the development of next-generation CAR-T cell therapies. At the heart of Optieum’s innovation is its proprietary Eumbody System, a revolutionary platform that optimizes CAR constructs to unlock the full therapeutic potential of T cells by dynamically harmonizing CAR binding domains. This transformative platform has the potential to redefine CAR-T cell therapy, enabling the development of groundbreaking treatments for challenging diseases. For more information, visit www.optieumbio.com and follow us on LinkedIn.

Contact:

Optieum Biotechnologies
Email: info@optieumbio.com